High-end Generic Drug - Global Market insights and Sales Trends 2024
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
High-end Generic Drug - Global Market insights and Sales Trends 2024
Generic drugs refer to similar drugs developed based on existing original drugs and are usually cheaper than the original drugs. The emergence of high-end generic drugs can effectively reduce patients' medical costs and promote the development of the pharmaceutical industry.
Global High-end Generic Drug market is projected to reach US$ million in 2029, increasing from US$ million in 2022, with the CAGR of % during the period of 2024 to 2029. Demand from Hospital and Pharmacy are the major drivers for the industry.
As people's demand for medical care increases, pharmaceutical technology advances and the prevalence of chronic diseases increases, and pharmaceutical R&D activities and investments increase, the high-end generic drug industry is developing well. However, the industry also faces various challenges, such as strict market supervision, high research and development costs, expiration of drug patents, and declining revenue. Companies need to continue to innovate and adapt to these challenges to remain competitive in the market. In addition, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for high-end generic pharmaceutical companies to be nimble in responding to emerging public health needs.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global High-end Generic Drug market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Companies, Type, Application and Regions Listed in the Report
Viatris
Teva
Organon
Sun Pharma
Bausch Health
Mylan NV
Novartis AG
Pfizer Inc
Fresenius SE & Co
Lupin Limited
Endo Pharmaceuticals Inc
Aurobindo Pharma Limited
Warner (India) Pharma Private Limited
Shijiazhuang Pharma Group
Fosun Pharma
Yangtze River Pharmaceutical Group
Sichuan KELUN PHARMACEUTICAL Co., Ltd.
Nantong Beite Pharmaceutical Machinery Co.,Ltd
CR Pharmaceutical Group
Segment by Type
Prescription Drugs
Non-prescription Drugs
Hospital
Pharmacy
Others
By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Latin America
Mexico
Brazil
Middle East & Africa
Turkey
Saudi Arabia
UAE
Each chapter of the report provides detailed information for readers to understand the High-end Generic Drug market further
Chapter 1Global and regional market size and CAGR for the history and forecast period (2018-2024, 2024-2029).
Chapter 2Product Types and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 3Product Application and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 4Company Competition Status, Detailed analysis of Product Name companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter 5Companies’ Outline, covering company’s basic information, High-end Generic Drug introduction, etc. High-end Generic Drug Revenue and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 6 to 10Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa by revenue.
Chapter 11Market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry.
Chapter 12Mr Accuracy reports’s Conclusions of High-end Generic Drug market based on comprehensive survey.
Chapter 13Methodology and Data Sources adopted by Mr Accuracy reports.
Global High-end Generic Drug market is projected to reach US$ million in 2029, increasing from US$ million in 2022, with the CAGR of % during the period of 2024 to 2029. Demand from Hospital and Pharmacy are the major drivers for the industry.
As people's demand for medical care increases, pharmaceutical technology advances and the prevalence of chronic diseases increases, and pharmaceutical R&D activities and investments increase, the high-end generic drug industry is developing well. However, the industry also faces various challenges, such as strict market supervision, high research and development costs, expiration of drug patents, and declining revenue. Companies need to continue to innovate and adapt to these challenges to remain competitive in the market. In addition, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for high-end generic pharmaceutical companies to be nimble in responding to emerging public health needs.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global High-end Generic Drug market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Companies, Type, Application and Regions Listed in the Report
By Company
Viatris
Teva
Organon
Sun Pharma
Bausch Health
Mylan NV
Novartis AG
Pfizer Inc
Fresenius SE & Co
Lupin Limited
Endo Pharmaceuticals Inc
Aurobindo Pharma Limited
Warner (India) Pharma Private Limited
Shijiazhuang Pharma Group
Fosun Pharma
Yangtze River Pharmaceutical Group
Sichuan KELUN PHARMACEUTICAL Co., Ltd.
Nantong Beite Pharmaceutical Machinery Co.,Ltd
CR Pharmaceutical Group
Segment by Type
Prescription Drugs
Non-prescription Drugs
Segment by Application
Hospital
Pharmacy
Others
By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Latin America
Mexico
Brazil
Middle East & Africa
Turkey
Saudi Arabia
UAE
Each chapter of the report provides detailed information for readers to understand the High-end Generic Drug market further
Chapter 1Global and regional market size and CAGR for the history and forecast period (2018-2024, 2024-2029).
Chapter 2Product Types and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 3Product Application and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 4Company Competition Status, Detailed analysis of Product Name companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter 5Companies’ Outline, covering company’s basic information, High-end Generic Drug introduction, etc. High-end Generic Drug Revenue and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 6 to 10Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa by revenue.
Chapter 11Market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry.
Chapter 12Mr Accuracy reports’s Conclusions of High-end Generic Drug market based on comprehensive survey.
Chapter 13Methodology and Data Sources adopted by Mr Accuracy reports.
Electronic and Semiconductor
Food and Beverages
Chemicals and Materials
Consumer Goods
Construction Manufacturing
Aerospace and Defence
Energy and Power
ICT Media
Banking and Finance
Automotive and Transportation
Machinery and Equipments
Pharmaceutical and Healthcare
Medical Devices